Drugs / 17β-oestradiol-3-phosphate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03821415 | Jan → Nov 2019 | dry eye syndrome | Redwood Pharma AB | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 17β-oestradiol-3-phosphate | “Redwood Pharma is developing the novel ophthalmic product RP101 containing the known active substance 17β-oestradiol-3-phosphate and based upon the drug delivery platform...” NCT03821415 ↗ |
| Known as | RP101 | “Redwood Pharma is developing the novel ophthalmic product RP101 containing the known active substance 17β-oestradiol-3-phosphate and based upon the drug delivery platform...” NCT03821415 ↗ |
| Route | Topical | “Topical 17-β-estradiol-3-phosphate eye drops were administered in three different dosage groups” PMID 33710587 ↗ Mar 2021 |